


## CLAIMS

1. A compound represented by the general formula (I):





wherein R<sup>1</sup> and R<sup>2</sup> represent a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub> alkyl group, a C<sub>3</sub>-C<sub>8</sub> alkenyl group or a benzyl group and at least one of R<sup>1</sup> and R<sup>2</sup> is a hydrogen atom, and R<sup>3</sup> represents a hydrogen atom or a hydroxyl group, or a pharmaceutically acceptable salt thereof.

2. A drug comprising the compound (I) according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

3. A TACE inhibitor comprising the compound (I) according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

4. A compound represented by the following formula (IIA) or

(IIB) :



wherein R<sup>1</sup> and R<sup>2</sup> represent a hydrogen atom, a C<sub>1</sub>-C<sub>8</sub> alkyl group, a C<sub>3</sub>-C<sub>8</sub> alkenyl group or a benzyl group, R<sup>3</sup> represents a hydrogen atom or a hydroxyl group, and CO-R<sup>4</sup> represents a hydroxamic acid equivalent.